Tilray Brands, Inc.

NasdaqGS:TLRY 주식 리포트

시가총액: US$631.0m

Tilray Brands 배당 및 자사주 매입

배당 기준 점검 0/6

Tilray Brands 배당금을 지급한 기록이 없습니다.

핵심 정보

n/a

배당 수익률

-15.7%

자사주 매입 수익률

총 주주 수익률-15.7%
미래 배당 수익률n/a
배당 성장률n/a
다음 배당 지급일n/a
배당락일n/a
주당 배당금n/a
배당 성향n/a

최근 배당 및 자사주 매입 업데이트

업데이트 없음

Recent updates

내러티브 업데이트 • May 17

TLRY: BrewDog Deal And Cannabis Rescheduling Will Shape Future Upside Potential

Analysts have trimmed their average price target on Tilray Brands by a few dollars to reflect updated assumptions around discount rates, profit margins and future P/E multiples, even as some highlight potential benefits from partial cannabis rescheduling and recent acquisitions. Analyst Commentary Bullish Takeaways Bullish analysts view the partial cannabis rescheduling order as extremely favorable, seeing scope for improved sector sentiment and potential support for valuation multiples if regulatory risk is perceived as lower.
내러티브 업데이트 • May 02

TLRY: BrewDog Acquisition And Cannabis Rescheduling Will Drive Future Upside

Analysts have cut their average price target on Tilray Brands to about $10.04 from $16.17, reflecting updated assumptions on discount rates, revenue growth, profit margins, and a reset future P/E following recent research that includes target reductions tied to the BrewDog asset acquisition and evolving views on potential U.S. cannabis rescheduling. Analyst Commentary Recent research on Tilray Brands highlights a mix of optimism around regulatory developments and caution around execution risks, especially following the BrewDog asset acquisition and a series of price target resets.
내러티브 업데이트 • Apr 18

TLRY: BrewDog Integration And Synergies Will Support Long Term Cash Flow Potential

The analyst price target for Tilray Brands has been reduced by several dollars to $9.00. This reflects analysts' focus on lower future P/E assumptions and execution risks around recent acquisitions, even as they factor in slightly higher revenue growth and profit margin estimates.
Seeking Alpha • Apr 09

Tilray Has Strong Synergies, But Sector Remains Weak

Summary Tilray reported strong Q3-2026 results earlier this month. The company has strong synergies with increasing global operations. The company is undervalued, but the sector is still weak due to uncertainty. The stock price is up 48% over the last year, but has still not recovered from its reverse split. I continue my rating of a Hold. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 04

TLRY: BrewDog Acquisition Execution Will Support Long Term Cash Flow Visibility

Tilray Brands' updated analyst price target framework now points to an implied fair value shift from $19.22 to $20.25. Analysts cite changes to revenue growth assumptions, profit margin expectations, and a higher future P/E multiple following a mix of price target cuts and a recent upgrade on the stock.
내러티브 업데이트 • Mar 20

TLRY: BrewDog Acquisition Synergies And Schedule III Shift Will Improve Cash Flow Visibility

Analysts have reduced their Tilray Brands price targets to $9.00 from $10.00, reflecting caution regarding the BrewDog asset acquisition and a focus on the company demonstrating it can achieve operational synergies, as well as provide clearer long term visibility into sales and cash flows. Analyst Commentary Recent research updates point to a cautious stance on Tilray Brands, with several Bearish analysts trimming price targets and reiterating more neutral views after both the BrewDog asset acquisition and the latest quarterly results.
내러티브 업데이트 • Mar 05

TLRY: Schedule III Shift And Medical Push Will Improve Cash Flow Visibility

Narrative Update on Tilray Brands The analyst price target for Tilray Brands has been trimmed from $9.25 to $9.00 as analysts factor in a slightly higher discount rate, a lower assumed future P/E, and execution risks and synergy uncertainty around the BrewDog asset acquisition, even though revenue growth and profit margin assumptions remain modestly higher. Analyst Commentary Recent Street research on Tilray Brands has leaned cautious, with multiple bearish analysts trimming price targets and maintaining neutral stances despite some operational positives.
내러티브 업데이트 • Feb 19

TLRY: Rescheduling And Licensing Agreements Will Support Long Term Cash Flow Visibility

Analysts have updated their price target on Tilray Brands to $19.22 from $1.83, reflecting revised assumptions around revenue growth, profit margins, and future P/E following recent coverage initiations and target resets that cited solid Q2 sales with mixed visibility on long-term sales and cash flow. Analyst Commentary Recent Street commentary around Tilray Brands has been mixed, with some firms trimming price targets while keeping ratings neutral.
내러티브 업데이트 • Feb 05

TLRY: Schedule III Rescheduling And Medical Expansion Will Support Cash Flow Visibility

Analysts have trimmed their price targets on Tilray Brands to around $10, reflecting a more cautious stance after recent quarterly results that they viewed as generally in line. Solid international and distribution sales were partly offset by ongoing questions around long term sales visibility and cash flow.
내러티브 업데이트 • Jan 21

TLRY: Schedule III Shift Will Test Medical Expansion And Cash Flow Visibility

Analysts have adjusted their fair value estimate for Tilray Brands from $8.50 to $9.25, citing recent target revisions that reflect more cautious revenue growth assumptions, steady profitability expectations, and an updated outlook for the future price-to-earnings ratio. Analyst Commentary Recent Street research has leaned cautious on Tilray Brands, with bearish analysts trimming price targets and flagging risks around visibility into the company’s longer term financial profile.
분석 기사 • Jan 16

Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 30% Price Drop

To the annoyance of some shareholders, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares are down a considerable 30% in the...
내러티브 업데이트 • Jan 06

TLRY: Rescheduling To Schedule III Will Expose Medical Expansion Hurdles

Analysts have lifted their fair value estimate for Tilray Brands to $8.50 from $0.60, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they see as better reflecting the company’s current risk and earnings profile. What's in the News President Trump signed an executive order directing Attorney General Pam Bondi to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act.
내러티브 업데이트 • Dec 20

TLRY: Reverse Split Will Drive Future Upside As Medical Expansion Advances

Analysts have modestly raised their price target on Tilray Brands to reflect slightly stronger long term revenue growth expectations, even as they factor in significantly compressed profit margins and a sharply higher assumed future price to earnings multiple. What's in the News Tilray Medical outlined a strategic framework for U.S. medical cannabis expansion following federal rescheduling, creating Tilray Medical USA Inc.
내러티브 업데이트 • Dec 06

TLRY: Reverse Split And Medical Expansion Will Drive Future Upside

Analysts have significantly raised their price target on Tilray Brands, lifting fair value expectations from approximately $1.78 to $16.17 per share, citing improved long term earnings visibility and a more favorable valuation multiple outlook. What's in the News Announced a 1 for 10 reverse stock split effective December 2, 2025, aiming to support continued Nasdaq listing and broaden institutional investor eligibility (company announcement).
분석 기사 • Nov 24

Tilray Brands, Inc. (NASDAQ:TLRY) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough

The Tilray Brands, Inc. ( NASDAQ:TLRY ) share price has fared very poorly over the last month, falling by a substantial...
내러티브 업데이트 • Nov 22

TLRY: Federal Policy Shifts Will Drive New U.S. Cannabis Opportunities

Analysts have raised Tilray Brands' price target from $1.50 to $2.00, citing strengthened expectations due to shifting U.S. federal policy toward cannabis and the company's strong market position. Analyst Commentary Analysts have highlighted a range of factors that support an optimistic outlook for Tilray Brands, while also noting certain risks that could affect the company's future performance.
내러티브 업데이트 • Nov 07

TLRY: Progress On U.S. Rescheduling Will Unlock New Market Access

Tilray Brands has received an increased analyst price target from $1.50 to $2.00 per share, reflecting greater optimism because of anticipated regulatory changes and the company’s strong industry positioning. Analyst Commentary Bullish analysts have reacted positively to recent developments affecting Tilray Brands, noting a number of factors that could drive further growth and improve the company’s outlook.
내러티브 업데이트 • Oct 23

Upcoming Federal Policy Shifts Will Open New Opportunities In Cannabis Markets

Analysts have raised their price target on Tilray Brands from $1.50 to $2.00, citing recent shifts in U.S. federal policy toward cannabis and the company's strong positioning to benefit from potential market expansion. Analyst Commentary Following the price target increase, analysts have shared both optimistic and cautious perspectives on Tilray Brands, reflecting on the company's future prospects and potential risks.
내러티브 업데이트 • Oct 09

Expanding European Cannabis Markets Will Unlock Global Wellness Potential

Analysts have raised their price target for Tilray Brands from $1.50 to $2.00, citing anticipated progress in U.S. cannabis policy and Tilray's strong positioning to benefit from broader market access. Analyst Commentary Recent commentary from bullish analysts highlights both the strengths and potential hurdles facing Tilray Brands in the evolving cannabis market.
분석 기사 • Oct 03

Tilray Brands, Inc.'s (NASDAQ:TLRY) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have continued their recent momentum with a 29% gain in the last month...
내러티브 업데이트 • Aug 26

Expanding European Cannabis Markets Will Unlock Global Wellness Potential

Tilray Brands’ consensus price target has increased to $0.983 as analysts cite improved U.S. political momentum toward cannabis rescheduling and Tilray’s strong positioning to benefit from expanding market opportunities. Analyst Commentary Positive political developments, with momentum towards rescheduling marijuana from Schedule I to Schedule III in the U.S., indicating a potential shift in federal cannabis policy.
분석 기사 • Aug 18

Tilray Brands, Inc. (NASDAQ:TLRY) Surges 66% Yet Its Low P/S Is No Reason For Excitement

Despite an already strong run, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares have been powering on, with a gain of 66% in...
분석 기사 • Jul 04

Tilray Brands, Inc. (NASDAQ:TLRY) Shares Fly 35% But Investors Aren't Buying For Growth

Tilray Brands, Inc. ( NASDAQ:TLRY ) shareholders are no doubt pleased to see that the share price has bounced 35% in...
User avatar
새로운 내러티브 • May 04

Integrated Operations Will Extend European And US THC Beverage Markets

Strategic initiatives focusing on margin improvements and global expansion efforts could significantly boost profitability and revenue growth.
Seeking Alpha • Apr 28

Tilray Brands Could Bounce Big

Summary Tilray Brands missed Q3 expectations but improved its balance sheet, with net debt at $14 million. Despite revenue and EBITDA misses, Tilray's valuation is attractive, trading at 6.85X projected FY27 adjusted EBITDA, suggesting potential gains of up to 77%. Risks include NASDAQ delisting and integration challenges from numerous acquisitions, but maintaining the NASDAQ listing is crucial. I remain optimistic due to Tilray's technical indicators and valuation, despite concerns about its cannabis operations and other business units. Read the full article on Seeking Alpha
Seeking Alpha • Apr 09

Tilray: Q3 Earnings Could Be The Inflection Point It Needs

Summary Tilray’s Q3 earnings show promising signs of improving fundamentals with expanding margins and effective cost management, combined with a clean balance sheet. Management’s strategy shift to prioritizing profitable growth offers a viable path to long-term profitability. Despite improving fundamentals, Tilray appears to be undervalued, in my opinion. I’m reiterating my buy rating for Tilray, while lowering my price target to $2.4, representing 419% upside from its current valuation. Read the full article on Seeking Alpha
분석 기사 • Mar 26

Lacklustre Performance Is Driving Tilray Brands, Inc.'s (NASDAQ:TLRY) 28% Price Drop

To the annoyance of some shareholders, Tilray Brands, Inc. ( NASDAQ:TLRY ) shares are down a considerable 28% in the...

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 과거에 TLRY 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: TLRY 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

배당 수익률 vs 시장

Tilray Brands 배당 수익률 vs 시장
TLRY의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (TLRY)n/a
시장 하위 25% (US)1.4%
시장 상위 25% (US)4.2%
업계 평균 (Pharmaceuticals)2.1%
분석가 예측 (TLRY) (최대 3년)n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 TLRY 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 TLRY 의 배당 수익률을 평가할 수 없습니다.

주주 대상 이익 배당

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 TLRY 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주 현금 배당

현금 흐름 범위: TLRY 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/26 02:33
종가2026/05/26 00:00
수익2026/02/28
연간 수익2025/05/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Tilray Brands, Inc.는 27명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Jesse PytlakATB Cormark Historical (Cormark Securities)